Stay updated with breaking news from Interventional Immunology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medigene AG: Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers Planegg/Martinsried (pta/21.12.2021/15:20) * MDG1011 was safe and well tolerated * Successful individual manufacturing of MDG1011 drug product from heavily pre-treated patients wi...
/PRNewswire/ -- In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in...
Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies. The new instrument h...
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 News provided by Share this article Share this article SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. "We are encouraged by our continued progress in first quarter of 2021, building on the accomplishm...
E-Mail The human genome contains roughly three million letters. On average, the genome sequences of any two people differ from each other by about one in every 1,000 letters. Yet different variants occur, from substituted letters to entire missing sections of DNA. Scientists from the Berlin Institute of Health (BIH) and the Regensburg Center for Interventional Immunology (RCI) have teamed up with Icelandic researchers to develop software that reliably and quickly identifies large deletions in ten-thousands of genomes simultaneously. The researchers have now published their findings in the j...